Literature DB >> 23337621

Correlation between micronuclei frequency in peripheral blood lymphocytes and retention of 131-I in thyroid cancer patients.

Olgica B Vrndić1, Olivera M Milošević-Djordjević, Ljiljana C Mijatović Teodorović, Marija Z Jeremić, Ivana M Stošić, Darko V Grujicić, Snezana T Zivancević Simonović.   

Abstract

Differentiated thyroid cancers (DTCs) derive from thyroid follicular cells and include papillary and follicular cancers. In patients with DTCs, the initial treatment includes thyroidectomy and radioactive iodine (131-I) therapy. The objective of this study was to examine whether the intensity of DNA damage in peripheral blood lymphocytes (PBLs) of DTC patients depends on the amount of 131-I retained in the selected regions of interest (thyroid and abdominal region) as well as in the whole-body 72 hours after therapy. In addition, the possible influence of other factors that may affect micronuclei (MN) frequency, such as age, gender, smoking habits, and histological type of tumour was analyzed. The study population consisted of 22 DTC patients and 20 healthy donors. Data on the distribution of 131-I were obtained from the whole-body scans. MN frequency and cytokinesis-block proliferation index (CBPI) were measured using cytokinesis-block micronucleus assay. 131-I therapy significantly increased the MN frequency (19.50±6.90 vs. 27.10±19.50 MN) and significantly decreased the CBPI (1.52±0.20 vs. 1.38±0.17) in patients' lymphocytes. There was a clear correlation between the increased MN frequency and 131-I accumulation in the thyroid region in patients without metastases. The MN values did not differ in relation to the factors that could affect MN, such as age, gender, smoking habits, and histological type of tumour. In conclusion, the MN frequency in PBLs of DTC patients without metastases depends on the accumulation of 131-I in the thyroid region and does not depend on the other factors examined.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23337621     DOI: 10.1620/tjem.229.115

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  5 in total

1.  Cytogenetic effects of radioiodine therapy: a 20-year follow-up study.

Authors:  Gordon K Livingston; Igor K Khvostunov; Eric Gregoire; Joan-Francesc Barquinero; Lin Shi; Satoshi Tashiro
Journal:  Radiat Environ Biophys       Date:  2016-03-25       Impact factor: 1.925

2.  Predictive factors of cytotoxic damage in radioactive iodine treatment of differentiated thyroid cancer patients.

Authors:  Satoru Monzen; Yasushi Mariya; Andrzej Wojcik; Chika Kawamura; Ayumi Nakamura; Mitsuru Chiba; Masahiro Hosoda; Yoshihiro Takai
Journal:  Mol Clin Oncol       Date:  2015-01-27

3.  Evaluation of in vitro antioxidant, antimicrobial, genotoxic and anticancer activities of lichen Cetraria islandica.

Authors:  Darko Grujičić; Ivana Stošić; Marijana Kosanić; Tatjana Stanojković; Branislav Ranković; Olivera Milošević-Djordjević
Journal:  Cytotechnology       Date:  2014-03-04       Impact factor: 2.058

Review 4.  Radiation and Thyroid Cancer.

Authors:  Elisabetta Albi; Samuela Cataldi; Andrea Lazzarini; Michela Codini; Tommaso Beccari; Francesco Saverio Ambesi-Impiombato; Francesco Curcio
Journal:  Int J Mol Sci       Date:  2017-04-26       Impact factor: 5.923

5.  Retrospective Biological Dosimetry at Low and High Doses of Radiation and Radioiodine Impact on Individual Susceptibility to Ionizing Radiation.

Authors:  Antonina Cebulska-Wasilewska; Mateusz Krzysiek; Grażyna Krajewska; Artur Stępień; Paweł Krajewski
Journal:  Genome Integr       Date:  2017-01-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.